Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Masimo Corp (MASI) reports robust healthcare revenue growth and improved margins, while navigating non-healthcare segment ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Joe Kiani Co-Founder Masimo Corp. The latest legal battle between Irvine-based medical device maker Masimo Corp. and Apple ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 38%. Looking ahead, revenue ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Masimo Corporation MASI delivered adjusted earnings per share (EPS) of 98 cents in the third quarter of 2024, up 30.7% year ...